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Introduction: Tubal ectopic pregnancy (tEP) is the
most common life-threatening condition in gynaecology.
tEPs with pretreatment serum human chorionic
gonadotrophin (hCG) levels <1000 IU/L respond well to
outpatient medical treatment with intramuscular
methotrexate (MTX). TEPs with hCG >1000 IU/L take a
significant time to resolve with MTX and require multiple
outpatient monitoring visits. Gefitinib is an orally active
epidermal growth factor receptor (EGFR) antagonist. In
preclinical studies, we found that EP implantation sites
express high levels of EGFR and that gefitinib augments
MTX-induced regression of pregnancy-like tissue. We
performed a phase I toxicity study administering oral
gefitinib and intramuscular MTX to 12 women with tEPs.
The combination therapy did not cause significant
toxicities and was well tolerated. We noted that
combination therapy resolved the tEPs faster than MTX
alone. We now describe the protocol of a larger single
arm trial to estimate the efficacy and side effects of
combination gefitinib and MTX to treat stable tEPs with
hCG 1000–10 000 IU/L
Methods and analysis:We propose to undertake a
single-arm multicentre open label trial (in Edinburgh and
Melbourne) and recruit 28 women with tEPs
(pretreatment serum hCG 1000–10 000 IU/L). We intend
to give a single dose of intramuscular MTX (50 mg/m2)
and oral gefitinib (250 mg) daily for 7 days. Our primary
outcome is the resolution of EP to non-pregnant hCG
levels <15 IU/L without requirement of surgery. Our
secondary outcomes are comparison of time to
resolution against historical controls given MTX only, and
safety and tolerability as determined by clinical/
biochemical assessment.
Ethics and dissemination: Ethical approval has been
obtained from Scotland A Research Ethics Committee
(MREC 11/AL/0350), Southern Health Human Research
Ethics Committee B (HREC 11180B) and the Mercy
Health Human Research Ethics Committee (R12/25).
Data will be presented at international conferences and
published in peer-reviewed journals.
Trial registration number: ACTRN12611001056987.
ARTICLE SUMMARY
Article focus
▪ Protocol of a study to determine:
▪ Is combination therapy with MTX and gefitinib
effective at resolving tEP?
▪ Is combination therapy with MTX and gefitinib
safe and well tolerated?
Key messages
▪ Tubal ectopic pregnancy (tEPs) with hCG levels
<1000 IU/L respond well to treatment with intra-
muscular MTX.
▪ tEPs with human chorionic gonadotrophin (hCG)
levels >1000 IU/L require multiple hospital visits
to resolve with MTX and often require surgery.
▪ Novel combination therapy of MTX and the oral
EGFR antagonist, gefitinib, could reduce the
number of hospital visits required to resolve
tEPs with hCG levels >1000 IU/L.
Strengths and limitations of this study
▪ This is a phase II exploratory efficacy trial, and
will be the ‘first in man’ to examine the efficacy
of gefitinib and MTX to treat tEPs with hCG
levels >1000 IU/L
▪ This is a ‘single arm’ trial. The data will be used
to inform a future large multicentre randomised
controlled trial comparing combination therapy
to conventional management of tEPs.
▪ The combination therapy described also has
potential use in other pregnancy disorders where
medical regression of placental tissue could be
useful, for example, molar disease and regres-
sion of placenta accrete postpartum.
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INTRODUCTION
Tubal ectopic pregnancy (tEP) is the most common life-
threatening condition in modern gynaecology in both
the developed and developing world.1 2 tEPs with pre-
treatment serum human chorionic gonadotrophin
(hCG) levels <1000 IU/L respond well to outpatient
medical treatment with an intramuscular injection of
methotrexate (MTX). Indeed, it has been suggested that
these tEPs could be managed safely, and equally efﬁ-
ciently by expectant management without medical inter-
vention.3–5 In contrast, single-dose MTX is only
cost-effective in women with serum hCG concentrations
<1500 IU/L.6 In tEPs with higher hCG levels (>60% of
total tEPs), emergency laparoscopic surgical excision
(with its inherent risks of damage to visceral organs)
remains the most effective treatment. tEPs with higher
hCG levels take a signiﬁcant time to resolve with MTX
and require multiple outpatient monitoring visits.
There, therefore, exists a need for more effective
medical treatments for tEPs with higher hCG levels to
reduce the need for emergency surgery and reduce the
time to resolution associated with MTX management.
Geﬁtinib is an orally active epidermal growth factor
receptor (EGFR) antagonist licensed to treat non-small-cell
lung cancer.7 In preclinical studies, we found that EP
implantation sites express high levels of EGFR and that
geﬁtinib augments MTX-induced regression of pregnancy-
like tissue.8 To translate this into clinical care, we per-
formed a phase I single-arm open-label dose-escalation
study administering a combination of 250 mg oral geﬁtinib
(one dose (n=3), three daily doses (n=3), seven daily doses
(n=6)) and intramuscular MTX (50 mg/m2) to 12 women
with tEPs.9 The combination therapy did not cause any sig-
niﬁcant toxicities, and was well tolerated. We noted that
resolution (fall in serum hCG to <15 IU/l) with combin-
ation therapy was faster than the median time for tEPs to
resolve with MTX alone when compared with contempor-
aneous controls (21 vs 32 days).
OBJECTIVES
The objective of this trial is to evaluate the efﬁcacy and
side effects of combination geﬁtinib and MTX to treat
tEPs (hCG 1000–10 000 IU/L).
METHODS AND ANALYSIS
Study design
Phase II single-arm multicentre open label trial
(Edinburgh and two sites in Melbourne).
Subjects
Twenty-eight women with tEPs with hCG levels 1000–
10 000 IU/L.
Study settings
We intend to recruit patients from gynaecology depart-
ments within NHS Lothian (UK), and Southern Health
and Mercy Health networks in Melbourne, Australia.
Sample size
We have calculated the sample size using A’Hern’s
formula for phase II one-stage designs.10 For treatment
of tEPs with hCG levels 1000–10 000 IU/L by MTX
/geﬁtinib to be considered effective, we expect a success
rate of at least 90%.11 However, a success rate of 70% or
less would be considered unacceptable. With 80% power
and a 5% level of signiﬁcance, 28 patients are required
to enable us to assess whether the proportion of patients
with a successful outcome to treatment is ≤70% or
≥90%. If 24, or more, patients have a successful
outcome, we can reject the hypothesis that the true efﬁ-
cacy of MTX /geﬁtinib is ≤70% and progress to a phase
III trial.
Inclusion criteria
Women aged between 18 and 45 years; pretreatment
serum hCG of 1000–10 000 IU/L (rising or static); ultra-
sound diagnosis of deﬁnite tEP (extrauterine gestational
sac with yolk sac and/or embryo, with or without cardiac
activity) or probable tEP (inhomogeneous adnexal mass
or extrauterine sac-like structure)12 performed by a clin-
ical team of trained, qualiﬁed and experienced ultraso-
nographers; no clinical evidence of intra-abdominal
bleeding; no pallor; no guarding/rigidity on abdominal
examination; stable blood pressure and heart rate;
haemoglobin on full blood examination at day 1
between 100 and 165 g/L).
Exclusion criteria
Women with a pregnancy of unknown location; evidence
of a signiﬁcant intra-abdominal bleed on ultrasound
deﬁned by free ﬂuid above the uterine fundus or the
surrounding ovary13; women with a history of any signiﬁ-
cant pulmonary disease; abnormal liver/renal/haemato-
logical indices; signiﬁcant pre-existing dermatological
conditions; signiﬁcant pre-existing gastrointestinal
medical illnesses; Japanese ethnicity.
Participant enrolment
All gynaecology consultants within NHS Lothian (UK),
Southern Health and Mercy Health (both Australia) will
be sent a letter informing them of the study and request-
ing permission to approach their patients. The clinical
research team in NHS Lothian, Southern Health and
Mercy Health will approach eligible women, provide
them with patient information sheets and offer them
the opportunity to discuss the trial, and obtain informed
consent. Consent will only be taken once the patient has
had ample time to read the patient information sheet
and had her questions answered.
Intervention
Eligible women will be given a single-dose intramuscular
MTX (50 mg/m2) injection with seven daily doses oral
geﬁtinib (250 mg). The geﬁtinib will be started on the
same date when the MTX injection is given.
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Data collection
Data storage
A log with the patients’ name and date of birth will be
kept along with their unique study number in a separate
ﬁle. All the data generated from the study will be stored
in an anonymised form in a bespoke database, which
will also be password protected. Only anonymised infor-
mation will be stored on this, and participants will only
be identiﬁable by their study number. All paperwork will
be kept in a locked ﬁling cabinet in a locked ofﬁce. All
data will be stored on university server (University of
Edinburgh) on a password-protected computer with
limited access to the research team, in accordance with
the Data Protection Act (UK).
Screening
A member of the research team will carry out a screen-
ing visit to assess eligibility. All data will be recorded on
a case record form and transferred to a secure database.
Participant log
The clinical research team will keep an electronic log of
women who fulﬁl the eligibility criteria, women who are
invited to participate in the study, women recruited and
women who leave the trial early. Reasons for non-
recruitment (eg, non-eligibility, refusal to participate,
administrative error) will also be recorded. We will
attempt to collect reasons for non-participation from
women who decline to take part after previously provid-
ing contact details. During the course of the study, we
will document reasons for withdrawal from the study
and loss to follow-up (ﬁgure 1).
Assessments
To monitor treatment response, we will follow protocols
used clinically for medical management with MTX.
Serum hCG levels will be measured on days 4, 7 and 11,
then weekly until hCG levels drop to non-pregnant
levels (<15 IU/L). Medical management will be discon-
tinued and patients will undergo surgery based on their
response to MTX and clinical picture (eg, clinical evi-
dence of intra-abdominal bleeding) following standard
clinical paradigms documented by the assessing clin-
ician. Participants will be contacted at 3 and 6 months
post-treatment to document return of menstrual cycles
and any subsequent pregnancies. To monitor safety and
tolerability, women will be assessed clinically (history)
and biochemically (haematological, renal and liver func-
tion tests) on days 4 and 7 (or if elevated, until return to
normal physiological levels).
Primary outcome
Our primary outcome is resolution of tEP without
requirement for surgery. Resolution is deﬁned by serum
hCG levels (the current clinical marker to monitor treat-
ment response) falling to non-pregnant levels (hCG
<15 IU/L). We have selected our primary outcome
based on the data from our phase I trial where two
patients recruited with pretreatment hCG levels
>1000 IU/L required surgery and previously published
data.14 We are using a cut-off of <15 IU/L, which corre-
sponds to a negative urinary pregnancy test using the
most sensitive assays.
Secondary outcome
I. Time to resolution (categorical variable) compared
with historical controls of similar pretreatment serum
hCG levels (identiﬁed by an individual blinded to
the study).
II. Safety and tolerability as determined by clinical and
biochemical assessment. Both MTX and geﬁtinib
have the potential to affect haematological, renal
and liver function.
Proposed analyses
Given this is a single arm efﬁcacy trial, the majority of
the data will be expressed as descriptive statistics.
Ethics and dissemination
Ethical approval has been obtained from the Scotland A
Research Ethics Committee (LREC 12/SS/0005) (UK),
the Southern Health Human Research Ethics
Committee B (SH HREC 11180B) and the Mercy Health
Human Research Ethics Committee (R12/25) (both
Figure 1 Flow chart of participants involved in the study.
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Australia). Data will be presented at international confer-
ences and published in peer-reviewed journals. We will
make the information obtained from the study available
to the public through national bodies and charities (eg,
Ectopic Pregnancy Trust).
Adverse events
Participants will collect information about adverse events
in their treatment diaries. However, they will be
instructed to contact the clinical research team at any
time after consenting to join the trial if they have an
event that requires hospitalisation or an event that
results in persistent or signiﬁcant disability or incapacity.
Any serious adverse events that occur after joining the
trial will be reported in detail in the participant’s
medical notes, followed up until resolution of the event
and reported to the ACCORD Research Governance
(http://www.accord.ed.ac.uk) and QA Ofﬁce based at
the University of Edinburgh, or the Southern Health/
Mercy Health Human Research Ethics Committees and
Therapeutic Goods Administration of Australia’s Ofﬁce
of Scientiﬁc Evaluation immediately or within 24–72 h.
DISCUSSION
If effective, we believe that this combination (geﬁtinib and
MTX) could become standard of care for stable tEPs. The
combination also has potential use in other pregnancy dis-
orders. There may be other important conditions where
medical regression of pregnancy tissue could be useful, for
example, women with complete molar pregnancies and
persistent molar disease and women with placenta accrete
postpartum (to avoid hysterectomy).
Regarding the safety of geﬁtinib, data from post mar-
keting surveillance representing over 92 000 patients
exist and have shown that EGFR inhibitors are well toler-
ated and largely free of serious side effects (Food and
Drug Administration (FDA) report).15 Of note, the data
on tolerability are based on patients taking geﬁtinib
daily on an ongoing, indeﬁnite basis, after primary treat-
ment of cancer. Diarrhoea and skin rash are the most
common side effects (20–30%). The skin rash, described
as acneiform, can be severe, but is generally self-limited.
Skin rashes occur within a month of initiation of treat-
ment, but rarely in the ﬁrst week. Interstitial lung
disease (ILD) is a very rare but a serious side effect of
geﬁtinib. It is a thickening of the lung parenchyma that
can be fatal in a third of cases. Of the 31 045 patients in
the USA who took geﬁtinib (reported to the FDA), 84
developed ILD (0.3%). We plan to administer seven
250 mg geﬁtinib tablets, one daily for only 7 days, in
addition to MTX. This is an extremely short duration of
treatment compared with geﬁtinib’s current marketing
indications and existing data usage. We would not
expect this short course to have an adverse long-term
effect on fertility but we will be assessing participants 3
and 6 months posttreatment to document return of
menstrual cycles and any subsequent pregnancies.
We do not anticipate that this will be the ﬁnal trial to
determine whether further exploration of combination
therapy with geﬁtinib and MTX is worthwhile. We hope
that the study will generate sufﬁcient ‘signal’ that geﬁti-
nib and MTX may be effective and safe, to support a
funding application for a larger trial with a comparative
group. Such a trial could be designed as an ‘equivalence’
trial in terms of treatment efﬁcacy between conventional
management and the geﬁtinib/MTX comparison. It
would aim to test the hypothesis that geﬁtinib/MTX was
superior in a range of outcomes prioritised by consumer
groups and clinicians. We anticipate that these outcomes
could include: time to resumption of normal activities,
SF-36 at intervals after treatment and patient satisfaction
scores. Outcomes of a subsequent pregnancy are also
important but would require long-term follow-up studies.
We anticipate that focus groups and surveys of patients
and clinicians would be required to deﬁne the outcomes
(other than efﬁcacy) of these studies.
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